← Leaderboards
Daniel Molina
Technical Resources Inc
$10,710,627
Attributed
$10,710,627
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.6M · FY2014–23$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$10,710,627 · 3
By mechanism
N02$9,237,467 · 1
N01$1,473,160 · 2
Top collaborators
No co-investigators on record.
Most similar at Technical Resources Inc
Same institution · by research overlap
- Melynda Holmes$232,659,786
- Sandra Butler$24,260,418
- Joan Saunders$59,957,928
Others in their field
Top investigators on “Contracts”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,154,975,474
- Leonard Freedman · Leidos Biomedical Research, Inc.$811,365,654
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Bambra Strokes · Ppd Development Lp$526,656,217
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
Research focus
ContractsMonitorContractorProtocols DocumentationData ReportingSiteDrug KineticsResourcesData ManagementClinical TrialsServicesCancer Prevention TrialExtramural ActivitiesEvaluationCocaineChemopreventive AgentEnsureMalignant NeoplasmsDivision Of Cancer PreventionClinical Research SiteCancer PreventionDocumentationInformaticsDatabases
Grant awards (13)
PHASE I COCAINE DRUG INTERACTION STUDY. TO6. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. 08/10/2023 - 02/09/2025. NIDA REF. NO. N01DA-19-8947.$202,331
N01 · FY2023 · DA · contact PI
FY23. TO5. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. 01/18/2022 - 04/16/2024. NIDA REF. NO. N01DA-19-8947.$8,958
N01 · FY2023 · DA · contact PI
CANCER PREVENTION CLINICAL TRIALS AUDITING & INFORMATICS SUPPORT$479,309
N02 · FY2019 · CA · contact PI
CANCER PREVENTION CLINICAL TRIALS AUDITING & INFORMATICS SUPPORT$1,750,000
N02 · FY2018 · CA · contact PI
IGF::OT::IGF Task Order 4 for Clinical Support for a phase 1 clinical interaction study between lorcaserin and cocaine POP: 08/18/2014 -08/17/2015.$24,964
N01 · FY2018 · DA · contact PI
CANCER PREVENTION CLINICAL TRIALS AUDITING & INFORMATICS SUPPORT$1,850,000
N02 · FY2017 · CA · contact PI
IGF::OT::IGF Task Order 4 for Clinical Support for a phase 1 clinical interaction study between lorcaserin and cocaine POP: 08/18/2014 -08/17/2015.$331,575
N01 · FY2017 · DA · contact PI
CANCER PREVENTION CLINICAL TRIALS AUDITING & INFORMATICS SUPPORT$1,850,000
N02 · FY2016 · CA · contact PI
IGF::OT::IGF Task Order 4 for Clinical Support for a phase 1 clinical interaction study between lorcaserin and cocaine POP: 08/18/2014 -08/17/2015.$172,813
N01 · FY2016 · DA · contact PI
CANCER PREVENTION CLINICAL TRIALS AUDITING & INFORMATICS SUPPORT$1,250,000
N02 · FY2015 · CA · contact PI
IGF::OT::IGF Task Order 4 for Clinical Support for a phase 1 clinical interaction study between lorcaserin and cocaine POP: 08/18/2014 -08/17/2015.$177,605
N01 · FY2015 · DA · contact PI
Cancer Prevention Clinical Trials Auditing & Informatics Support.$2,058,158
N02 · FY2014 · CA · contact PI
IGF::OT::IGF Task Order 4 for Clinical Support for a phase 1 clinical interaction study between lorcaserin and cocaine POP: 08/18/2014 -08/17/2015.$554,914
N01 · FY2014 · DA · contact PI